ICW Investment Advisors LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY)

ICW Investment Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 9.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 423 shares of the company’s stock after buying an additional 38 shares during the quarter. ICW Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Lipe & Dalton purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $26,000. Thompson Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $27,000. Legacy Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $35,000. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc purchased a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $776.75 on Thursday. The business’s fifty day moving average price is $762.03 and its two-hundred day moving average price is $669.96. The stock has a market cap of $738.04 billion, a PE ratio of 114.40, a price-to-earnings-growth ratio of 1.58 and a beta of 0.37. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a one year low of $399.26 and a one year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 59.28% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. Eli Lilly and Company’s quarterly revenue was up 26.0% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 13.5 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $885.00 price target (up previously from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. JPMorgan Chase & Co. upped their price target on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a report on Wednesday. BMO Capital Markets upped their price target on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a report on Wednesday. The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Barclays upped their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average target price of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.